About Large ribosomal subunit protein uL3
Large ribosomal subunit protein uL3 (RPL3) is a protein
from Homo sapiens identified by UniProt accession
P39023, 403 residues long.
MolForge cross-references it against 0 known binders and
79 disease associations.
Target properties
| Protein name | Large ribosomal subunit protein uL3 |
| UniProt accession | P39023 |
| Gene | RPL3 |
| Organism | Homo sapiens |
| Length | 403 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (79)
Diseases linked to this target (Open Targets).
- Duchenne muscular dystrophy · score 0.50
- cystic fibrosis · score 0.50
- influenza · score 0.46
- Becker muscular dystrophy · score 0.29
- clear cell renal carcinoma · score 0.27
- endometrial cancer · score 0.27
- qualitative or quantitative defects of dystrophin · score 0.26
- ulcerative colitis · score 0.18
- interstitial lung disease · score 0.18
- inflammatory bowel disease · score 0.17
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P39023-F1 | alphafold | PREDICTED | 96.36 | — |
Amino-acid sequence (403 residues)
MSHRKFSAPR HGSLGFLPRK RSSRHRGKVK SFPKDDPSKP VHLTAFLGYK AGMTHIVREV DRPGSKVNKK EVVEAVTIVE TPPMVVVGIV GYVETPRGLR TFKTVFAEHI SDECKRRFYK NWHKSKKKAF TKYCKKWQDE DGKKQLEKDF SSMKKYCQVI RVIAHTQMRL LPLRQKKAHL MEIQVNGGTV AEKLDWARER LEQQVPVNQV FGQDEMIDVI GVTKGKGYKG VTSRWHTKKL PRKTHRGLRK VACIGAWHPA RVAFSVARAG QKGYHHRTEI NKKIYKIGQG YLIKDGKLIK NNASTDYDLS DKSINPLGGF VHYGEVTNDF VMLKGCVVGT KKRVLTLRKS LLVQTKRRAL EKIDLKFIDT TSKFGHGRFQ TMEEKKAFMG PLKKDRIAKE EGA
Explore Large ribosomal subunit protein uL3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets